Almstead Neil Gregory sold $693K of PTCT
Almstead Neil Gregory (CHIEF TECHNICAL OPS OFFICER) sold 8,130 shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $85.26 ($85.23–$85.26, $0.69M total) across 2 trades on 2026-06-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider’s holdings and confirms the sale’s timing, share count, and price range, but it does not introduce new fundamentals (no earnings, trial, or regulatory developments).
Market read
Traders may treat this as a sentiment datapoint rather than a catalyst; any price effect is likely small due to the 10b5-1 framing.
What to watch
The article doesn’t state whether the sale was part of a larger planned cadence, nor does it include options/other transactions—so interpreting intent is limited.
Background
This is an SEC Form 4 insider transaction for PTC Therapeutics (PTCT) by its Chief Technical Operations Officer, reported as an open-market sale under a pre-arranged 10b5-1 plan.
Ticker impact
PTC Therapeutics insider Almstead Neil Gregory sold $693K of PTCT shares via a 10b5-1 plan, disclosing trade size and price range.
Low near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 structure.
The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, and it contains no new company-specific operational or financial information.
Market effects
Minimal; single-company insider sale without accompanying guidance/clinical/regulatory updates.
None indicated.
None indicated.
Counterpoint
Even 10b5-1 sales can coincide with periods of perceived valuation risk; traders may still watch for follow-on selling or clustering of insider dispositions.
Key entities
- issuerPTC THERAPEUTICS, INC.
Subject of the Form 4 insider sale; shares sold and remaining holdings are disclosed.
- insiderAlmstead Neil Gregory
Chief Technical Operations Officer who executed the open-market sale under a 10b5-1 plan.
